Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
07 2019
Historique:
received: 26 06 2018
revised: 06 03 2019
accepted: 14 03 2019
pubmed: 3 4 2019
medline: 5 6 2020
entrez: 3 4 2019
Statut: ppublish

Résumé

Pallidal deep brain stimulation (DBS) has shown to be beneficial in patients with advanced levodopa-responsive Parkinson's disease (PD) in several short-term studies. However, reported long-term outcomes of pallidal DBS for PD are limited and contradictory. Eighteen consecutive PD patients were treated with unilateral or bilateral stimulation of the internal part of the globus pallidus (GPi). Assessments were carried out before and six months after neurosurgery, and annually thereafter for up to 16 years (mean follow-up time: 6 years). Primary outcomes included motor signs (Unified PD Rating Scale [UPDRS]-III), activities of daily living (ADL, UPDRS-II), and levodopa-induced motor complications (UPDRS-IV). The results show that GPi stimulation improves levodopa-responsive PD motor signs (UPDRS-III), levodopa-induced motor complications (UPDRS-IV), and ADL (UPDRS-II) in advanced PD. Among motor signs, tremor showed the best response to pallidal stimulation. Levodopa-induced motor complications and tremor showed improvements for more than 10 years after neurosurgery. The overall findings in our cohort demonstrate that pallidal stimulation is effective in reducing parkinsonian motor signs (UPDRS-III), particularly in the 'off'-medication state. Although the beneficial effects on bradykinesia, rigidity and ADL may be limited to 5-6 years, the follow up results indicate that the improvements of levodopa-induced motor complications (UPDRS-IV) and tremor can be sustained for more than 10 years.

Sections du résumé

BACKGROUND
Pallidal deep brain stimulation (DBS) has shown to be beneficial in patients with advanced levodopa-responsive Parkinson's disease (PD) in several short-term studies. However, reported long-term outcomes of pallidal DBS for PD are limited and contradictory.
METHODS
Eighteen consecutive PD patients were treated with unilateral or bilateral stimulation of the internal part of the globus pallidus (GPi). Assessments were carried out before and six months after neurosurgery, and annually thereafter for up to 16 years (mean follow-up time: 6 years). Primary outcomes included motor signs (Unified PD Rating Scale [UPDRS]-III), activities of daily living (ADL, UPDRS-II), and levodopa-induced motor complications (UPDRS-IV).
RESULTS
The results show that GPi stimulation improves levodopa-responsive PD motor signs (UPDRS-III), levodopa-induced motor complications (UPDRS-IV), and ADL (UPDRS-II) in advanced PD. Among motor signs, tremor showed the best response to pallidal stimulation. Levodopa-induced motor complications and tremor showed improvements for more than 10 years after neurosurgery.
CONCLUSIONS
The overall findings in our cohort demonstrate that pallidal stimulation is effective in reducing parkinsonian motor signs (UPDRS-III), particularly in the 'off'-medication state. Although the beneficial effects on bradykinesia, rigidity and ADL may be limited to 5-6 years, the follow up results indicate that the improvements of levodopa-induced motor complications (UPDRS-IV) and tremor can be sustained for more than 10 years.

Identifiants

pubmed: 30935828
pii: S1353-8020(19)30102-6
doi: 10.1016/j.parkreldis.2019.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-123

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

M L Lachenmayer (ML)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: lenard.lachenmayer@insel.ch.

C Bettschen (C)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

C Bernasconi (C)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

K Petermann (K)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

I Debove (I)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

J Muellner (J)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

J P Michelis (JP)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

J M Burgunder (JM)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

J K Krauss (JK)

Department of Neurosurgery, Medical School Hannover (MHH), Hannover, Germany.

M F Oertel (MF)

Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland.

C Pollo (C)

Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland.

A Kaelin-Lang (A)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurocentro della Svizzera Italiana, Ospedale Regionale di Lugano, Lugano, Switzerland.

M Schüpbach (M)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH